PMID- 38130399
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20240228
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Changes in serum tumor markers in type 2 diabetes mellitus with microalbuminuria.
PG  - 1247099
LID - 10.3389/fendo.2023.1247099 [doi]
LID - 1247099
AB  - OBJECTIVES: The objective of this study was to investigate changes in serum tumor 
      markers in type 2 diabetes mellitus (T2DM) with microalbuminuria and analyze the 
      relationship between tumor markers and microalbuminuria. METHODS: A total of 956 
      T2DM patients aged 40-70 years hospitalized in the Department of Endocrinology, 
      Xinhua Hospital, China, affiliated with Shanghai Jiaotong University School of 
      Medicine, were enrolled from January 2018 to December 2020. The sample comprised 
      313 T2DM patients with microalbuminuria and 643 T2DM patients with normal urinary 
      microalbumin levels. After assessing the changes in serum tumor markers in T2DM 
      with microalbuminuria, we analyzed the risk of microalbuminuria by the serum 
      tumor marker category using multiple logistic regression analysis. RESULTS: Serum 
      CEA, CA199, CA125, CA153, CA211, SCC, CA242, and CA50 levels were significantly 
      higher in T2DM patients with microalbuminuria than in those without 
      microalbuminuria, while serum AFP levels were lower in the microalbuminuria group 
      (P < 0.05). Following adjustment of confounders, serum CEA, CA211, and SCC were 
      independently associated with microalbuminuria in T2DM. An ROC curve was used to 
      estimate the cutoff point of tumor markers for microalbuminuria. Taking the 
      values under the cutoff points as a reference, values for CEA, CA211, and SCC 
      above the cutoff points indicated a significantly high risk of microalbuminuria. 
      The OR of increased CEA for microalbuminuria was 2.006 (95%CI 1.456-2.765), the 
      OR of increased CA211 for microalbuminuria was 1.505 (95%CI 1.092-2.074), and the 
      OR of increased SCC for microalbuminuria was 1.958 (95%CI 1.407-2.724). 
      CONCLUSION: Several serum tumor markers were related to microalbuminuria in T2DM. 
      Serum tumor markers such as CEA, SCC, and CA211 may indicate early diabetic 
      nephropathy, particularly when elevated in combination.
CI  - Copyright (c) 2023 Chen, Du, Li, Su, Zhang and Zhang.
FAU - Chen, Lina
AU  - Chen L
AD  - Department of Endocrinology, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Du, Shichun
AU  - Du S
AD  - Department of Endocrinology, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Li, Yan Bo
AU  - Li YB
AD  - Department of Endocrinology, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Su, Qing
AU  - Su Q
AD  - Department of Endocrinology, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Zhang, Jiangrong
AU  - Zhang J
AD  - Health Management Center, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
FAU - Zhang, Hongmei
AU  - Zhang H
AD  - Department of Endocrinology, Xinhua Hospital Affiliated with Shanghai Jiaotong 
      University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231207
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - Biomarkers, Tumor
MH  - *Diabetes Mellitus, Type 2/complications
MH  - China/epidemiology
MH  - *Neoplasms/complications
MH  - *Diabetic Nephropathies/complications
PMC - PMC10733510
OTO - NOTNLM
OT  - UACR
OT  - diabetes mellitus
OT  - microalbuminuria
OT  - tumor markers
OT  - type 2
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/12/22 06:43
MHDA- 2023/12/25 06:43
PMCR- 2023/01/01
CRDT- 2023/12/22 03:48
PHST- 2023/06/25 00:00 [received]
PHST- 2023/11/20 00:00 [accepted]
PHST- 2023/12/25 06:43 [medline]
PHST- 2023/12/22 06:43 [pubmed]
PHST- 2023/12/22 03:48 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1247099 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Dec 7;14:1247099. doi: 
      10.3389/fendo.2023.1247099. eCollection 2023.